The contractile mechanism of N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) was investigated in the guinea-pig Taenia coli, by simultaneously monitoring the changes in the cytosolic Ca2+ concentration ([Ca2+]i) and force. fMLP induced a significant elevation of [Ca2+]i and force at concentrations higher than 10 nM. The maximal response was obtained at a concentration of higher than 1 μM. fMLP (10 μM) augmented the force development induced by a stepwise increment of the extracellular Ca2+ concentration during 60 mM K+ depolarization, while it had no effect on the [Ca2+]i elevation, and thus produced a greater force for a given elevation of [Ca2+]i than 60 mM K+ depolarization. The removal of extracellular Ca2+ completely abolished the fMLP-induced contraction. The fMLP-induced [Ca2+]i elevation was inhibited substantially but not completely by 10 μM diltiazem, partly by 10 μM SK&F 96365, and completely by their combination. Y27632, a specific inhibitor of rho-kinase, had no significant effect on the fMLP-induced [Ca2+]i elevation and force development. Chenodeoxycholic acid, a formyl peptide receptor antagonist, specifically abolished the fMLP-induced contraction but not high K+- or carbachol-induced contractions. A dual lipoxygenase/cyclooxygenase inhibitor, a 5-lipoxygenase inhibitor, a nonselective leukotriene receptor antagonist, and a selective type 1 cysteinyl-containing leukotriene receptor antagonist specifically reduced the fMLP-induced contraction. We suggest that the low-affinity-type fMLP receptor and lipoxygenase metabolites of arachidonic acid are involved in the fMLP-induced contraction in the guinea-pig T. coli. This contraction mainly depends on the [Ca2+]i elevation due to Ca2+ influx and the enhancement of Ca2+ sensitivity in the contractile apparatus. Keywords: Ca2+ sensitivity, fMLP, gastrointestinal smooth muscle Introduction N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP), a synthetic analogue of bacterial chemotactic peptide (Schiffmann et al., 1975a, 1975b; Marasco et al., 1984), exerts a potent chemoattractant effect toward neutrophils and monocytes. In addition to this effect, fMLP has been shown to possess spasmogenic properties in smooth muscle tissues including airway, blood vessels, intestinal tract, and renal pelvis (Hamel et al., 1984; Armour et al., 1986; Boukili et al., 1986; Shore et al., 1987; Crowell et al., 1989; Maggi et al., 1992; Minamino et al., 1996). The mechanism for the fMLP-induced contraction appeared to vary with type of smooth muscle tissue. Many studies have suggested an indirect contractile mechanism in the human bronchus, guinea-pig lung parenchymal strips, human coronary artery, and rabbit pulmonary artery (Hamel et al., 1984; Armour et al., 1986; Shore et al., 1987; Crowell et al., 1989; Keitoku et al., 1997). The cyclooxygenase and lipoxygenase metabolites of arachidonic acid, such as thromboxane A2 and leukotriene C4, were suggested to mediate the contractile response of fMLP, based on the observation that the inhibitors of cyclooxygenase (Hamel et al., 1984; Shore et al., 1987; Crowell et al., 1989; Keitoku et al., 1997), lipoxygenase (Shore et al., 1987) and thromboxane synthase (Shore et al., 1987), or leukotriene receptor antagonist (Armour et al., 1986; Shore et al., 1987) inhibited the fMLP-induced contraction. The fMLP-activated neutrophils have also been shown to induce endothelium-dependent contraction in the human umbilical vein and canine coronary artery (Minamino et al., 1996; Kerr et al., 1998). On the other hand, the direct contractile effect of fMLP has only been suggested in the guinea-pig ileum (Marasco et al., 1982). Furthermore, the cellular mechanism for fMLP-induced contraction remains to be elucidated, especially in terms of intracellular Ca2+ signal transduction. The cellular effect of fMLP is mediated by formyl peptide receptors. Three genes for humans (formyl peptide receptor (FPR), FPRL1, and FPRL2) and eight genes for mice (FPR1, FPR-rs1, 2, 3, 4, 5, 6, and 7) have been identified as FPR gene family (Bao et al., 1992; Gao et al., 1998; Wang & Ye, 2002). This receptor family belongs to a superfamily of a seven-transmembrane, G-protein-coupled receptor (Prossnitz & Ye, 1997). Among these receptors, FPR and FPRL1 in humans and FPR1 and FPR-rs1 in mice could serve as functional receptors for fMLP. The cellular distribution of the high-affinity FPR is not restricted to phagocytic leukocytes as originally proposed, but it is expressed on a broad spectrum of tissues and cells, including neuromuscular, vascular, endocrine, and immune systems (Lacy et al., 1995; McCoy et al., 1995; Sozzani et al., 1995; Becker et al., 1998; Panaro & Mitolo, 1999). FPRL1 is also expressed in a variety of cell types including phagocytic leukocytes, lymphocytes, hepatocytes, epithelial cells, neuroblastoma cells, astrocytoma cells, and microvascular endothelial cells (Gronert et al., 1998; Le et al., 2000). However, the receptor responsible for the fMLP-induced contractile responses remains to be identified. In the present study, we investigated the mechanism of the fMLP-induced contraction in the guinea-pig Taenia coli, by simultaneously monitoring the cytosolic Ca2+ concentrations ([Ca2+]i) and force development in the fura-PE3-loaded strips. The cellular mechanism of the fMLP-induced contraction was investigated in terms of Ca2+ signaling, by examining the effect of the removal of the extracellular Ca2+, two Ca2+ entry blockers, and a rho-kinase inhibitor. The receptor mediating the fMLP-induced contraction in the guinea-pig T. coli was evaluated by examining the effects of various receptor antagonists including chenodeoxycholic acid, the formyl peptide receptor antagonist, on the fMLP-induced contraction. We also investigated the involvement of the lipoxygenase metabolites of arachidonic acid in the fMLP-induced contraction.